ahead next tuesday result analyz novemb decemb us
sale trend use proprietari db med-tech databas monitor intra-quart
trend avoid blow-up like report last week remind get
data day month-end due time mdt earn releas
month data avail preview
use db med-tech databas model allow us track us revenu
world-wide two month data made model
adjust across mdt segment put
take net chang total sale forecast immateri
pleas see note addit detail highlight key estim chang
reduc crhf rev reduc us spine rev
maintain rtg specialti therapi reduc rtg brain therapi
maintain mitg revenue growth
preview look close sale trend key product
focu late among investor includ icds/pacemak still mix
bag data indic crt-d pressur may final abat tyrx
suppli issu may persist longer anticip interstim
surprisingli sale data point impact axonicss launch
net-net model revis result revenu estim rev
ep put us slightli consensu revenu ahead
consensu ep upper rang mdt guidanc
price feb usd
deutsch bank seek busi compani cover research report thu investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis disclosur analyst certif locat
distribut gmt
made sever minor adjust
revenu model driven db us med-tech databas figur
november/decemb net result modest decreas total sale estim
tad street note due time mdt earn releas two three month data
 model unchang ep remain penni consensu upper end guidanc
expens margin revenue
move estim tad lower continu headwind persist tyrx suppli issu
estim unchang expect continu tavr strength off-set de
estim unchang expect continu dcb weak consist
estim lower modestli still see growth come well broader spine market
temper us growth forecast one point
estim unchang db data point us interstim sale hit launch
estim unchang focu
db estim line guidanc
db estim includ contribut titan spine versu organ guidanc
db estim consist guidanc
estim unchang db estim line flat-to-slightly-down compani outlook
estim unchang hugo timelin updat focal point
db estim inclus titan spine contribut versu organ growth guidanc
flat sequenti yr/yr due mainli fx
flat yr/yr expect modest underli improv off-set fx
db upper end guidanc rang
us sale data november/decemb point crhf segment perform trend somewhat
prior forecast headwind plagu segment perform recent quarter look
eas somewhat includ tough lvad comp final anniversari
mani move part consid examin close model us crhf sale
growth modestli previous
cvg segment total cc forecast consist guidanc
base data estim tachi account us crhf sale convent icd
tradit icd remain pressur data show improv sequenti though still
drag total crhf growth
heart failur side crt-d look improv materi versu noteworthi given
crt-d replac cycl headwind huge drag overal segment perform
past quarter consist commentari prior call headwind start
abat net neutral data evid continu trend
estim bradi repres us crhf sale convent pacer account thank
substanti share captur reap uptak micra tcp
data show modest sequenti improv convent pacer meaning improv
crt categori though latter repres rel much smaller piec crhf revenu pie
db data indic micra penetr within initi indic segment av block concomit af
clearli start flatten past coupl quarter
importantli next-gener micra av fda approv late last month thu allow
address patient av block normal atrial function highli differenti leadless platform
micra av tripl address market estim total patient popul
indic perman pacemak expect potenti meaning reacceler medtron
low-voltag franchis next sever quarter
within us sale dataset hvad account total us crhf sale though note
figur north prior multitud issu plagu busi begin
expect db data show significantli better perform heartwar franchis thank
larg part difficult comp anniversari
technolog adopt point still rel modest tyrx present account crhf sale
mix within us sale sampl
recal suppli disrupt led precipit sale declin last quarter
though call
manag character issu relat shift
product facil new jersey
minnesota transient expect product would fulli restor normal level
unencumb suppli entireti
howev despit modest sequenti improv db data show tyrx sale growth continu
neg decemb suggest suppli disrupt may proven
endur initi anticip needless say key area focu next week call
despit nearer-term challeng continu think tyrx could ultim becom substanti revenu
contributor mdt franchis next year light robust data saw last year
reduct major
implant penalti vi -- vi procedur time advers event
db data point continu weak tyrx suggest protract suppli disrupt
tyrx asp rel stabl past sever quarter modest steadi declin like
reflect volume-driven discounts/reb realiz custom adopt increas
cardiac vascular group db segment revenu build
spine perform import focu next week result expect post
above-market growth though tad slower sequenti
spine drag mdt top line past sever year thank intens competit smaller player
relentless implant price pressur still account total compani sale higher mix profit
highli encourag meaning better segment perform late
health broader market clearli improv evidenc healthi result post pure play like
note nass overal market growth look settl rang
consist think
mdt franchis organ growth last quarter us ww best year reflect strength
infus broadli surgic synergi strategi clearli start bear fruit capit equip robot
navig imag help boost sale core implant
light latest sale data temper us spine sale growth forecast tad versu
previous report basi inclus titan spine
light latest sale data temper us spine sale growth forecast tad versu
previous report basi inclus titan spine
note incorpor titan spine deal close last june spine sale tracker model estim
titan repres us segment sale
specialti therapi franchis model presum us sale growth consist prior
quarter db data november/decemb point sale trend likewis remain steadi versu henc leav
forecast intact
axon indic octob built us commerci clinic support team base
initi check clear enthusiasm amongst urologist around axon product particularli given
give clinicians/pati option recharg system interstim current avail primari cell
technolog gap recharg offer transient expect launch
interstim micro back half pma supplement file octob volum actual
even smaller axon
said evidenc sale data novemb decemb sure see impact growth
interstim least near term
brain therapi franchis previous model us sale growth less flat
sequenti howev db data decemb point sequenti slower growth latest period base
weve temper estim one percentag point yield million lower project sale
db data decemb point modest sequenti growth deceler consist
think henc mitg segment sale estim unchang
world-wide mitg sale growth estim within guidanc rang
signific technolog gap medtron us diabet portfolio taken big toll segment perform sale
growth neg past three quarter model show remain case well
compani recent launch pathway initi enabl patient whose pump
warranti new pump therapi buy abil upgrad launch
charg extent help stem near-term bleed us franchis great interest
regard note result us pivot trial forthcom coupl week attd meet
also point segment perform also neg impact on-going recal lot
insulin pump total unit recal
model us segment sale declin world-wide cc revenu flat versu year ago
